Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Conference News AHA 2017

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

Shelley Wood

November 14, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Blood in Urine Carries Consequences for Patients on Antithrombotics

Yael L. Maxwell

October 09, 2017

News Daily News

Generic ARBs Linked to Increased Adverse Events

Michael O'Riordan

October 04, 2017

News Daily News

Acute MI Patients With Cancer History Less Likely to Get Evidence-Based Therapies

L.A. McKeown

September 25, 2017

News Daily News

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Michael O'Riordan

September 21, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Leah Lawrence

August 01, 2017

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

News Conference News SCCT 2017

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

Yael L. Maxwell

July 13, 2017

News Conference News EAS 2017

Perceived Financial Barriers to Healthcare Worsen Cardiovascular Outcomes Even in Countries With Universal Medical Coverage

Yael L. Maxwell

April 27, 2017

News Daily News

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Michael O'Riordan

April 27, 2017

Advertisement

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Blood in Urine Carries Consequences for Patients on Antithrombotics

Generic ARBs Linked to Increased Adverse Events

Acute MI Patients With Cancer History Less Likely to Get Evidence-Based Therapies

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

Perceived Financial Barriers to Healthcare Worsen Cardiovascular Outcomes Even in Countries With Universal Medical Coverage

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content